Innoviva, Inc. (INVA) income statement
INVANasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày Sep 30, 2026Last filing: 10-Q on Nov 4, 2026Score 14/3039% below fair value
$18.40+0.10 (+0.55%)
Close on Nov 18, 2026Market cap $1.33BP/E 9.3Yield –
Innoviva, Inc. income statement
Ratios
Latest available, balances at Sep 30, 2026
Profitability, TTM
- Gross margin
- 74.5%
- Operating margin
- 38.8%
- Net margin
- –
- Return on equity, FY2025
- –
Financial strength
- Current ratio
- 15.44
- Debt to equity
- 0.23
- Debt to assets
- 16.8%
- Cash to current liabilities
- 1162.1%
Valuation
- P/E ratio
- 9.3
- Price to sales
- 3.03
- Price to book
- 1.17
- Dividend yield
- –
See a number that looks wrong?